Analysts Set Envista Holdings Co. (NYSE:NVST) PT at $20.38

Shares of Envista Holdings Co. (NYSE:NVST - Get Free Report) have earned a consensus rating of "Hold" from the fourteen research firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and three have issued a buy rating on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $20.08.

NVST has been the subject of a number of research reports. New Street Research set a $19.00 target price on shares of Envista in a research note on Thursday, March 6th. Piper Sandler reduced their price objective on Envista from $18.00 to $17.00 and set a "neutral" rating for the company in a research report on Wednesday, April 30th. Morgan Stanley set a $16.00 target price on Envista in a research report on Tuesday, April 15th. Jefferies Financial Group upped their price target on shares of Envista from $20.00 to $22.00 and gave the company a "hold" rating in a research report on Thursday, January 23rd. Finally, Wells Fargo & Company set a $19.00 price objective on shares of Envista in a report on Saturday, March 8th.

Envista Stock Up 2.7 %

Shares of Envista stock traded up $0.45 on Friday, reaching $16.84. The company's stock had a trading volume of 2,322,676 shares, compared to its average volume of 2,526,487. Envista has a 52 week low of $14.22 and a 52 week high of $23.00. The firm's fifty day simple moving average is $16.59 and its two-hundred day simple moving average is $19.03. The company has a quick ratio of 1.76, a current ratio of 2.04 and a debt-to-equity ratio of 0.44. The company has a market capitalization of $2.85 billion, a price-to-earnings ratio of -2.59, a P/E/G ratio of 1.27 and a beta of 0.97.

Envista (NYSE:NVST - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.04. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%. The business had revenue of $616.90 million for the quarter, compared to analysts' expectations of $608.17 million. During the same quarter in the prior year, the business earned $0.26 EPS. The business's revenue for the quarter was down 1.1% compared to the same quarter last year. Equities analysts anticipate that Envista will post 1 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in Envista during the 4th quarter valued at approximately $53,000. Lecap Asset Management Ltd. purchased a new position in Envista during the fourth quarter valued at $281,000. Hantz Financial Services Inc. increased its holdings in Envista by 146.6% in the 4th quarter. Hantz Financial Services Inc. now owns 110,489 shares of the company's stock valued at $2,131,000 after acquiring an additional 65,679 shares during the last quarter. Norges Bank purchased a new stake in Envista in the 4th quarter worth $38,052,000. Finally, Natixis Advisors LLC lifted its position in shares of Envista by 1.8% in the fourth quarter. Natixis Advisors LLC now owns 106,652 shares of the company's stock worth $2,057,000 after buying an additional 1,845 shares in the last quarter.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.